Close Menu

NEW YORK(GenomeWeb) – Qiagen today announced that it has received a CE-IVD mark for its therascreen EGFR RGQ Plasma PCR kit, a liquid biopsy companion diagnostic to guide treatment for patients with non-small cell lung cancer.

The test, co-developed by Qiagen and AstraZeneca, is intended to help physicians identify which advanced NSCLC patients are more likely to benefit from treatment with AstraZeneca's EGFR inhibitor Iressa (gefitinib) in cases where when a suitable tumor tissue sample is not available.  

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.